Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Once drug patent expires is the drug usually moved to tier 3 by health care prividers in us?

What happens to a drug’s formulary tier after a patent expires in the US?

Patent expiry often changes the competitive landscape (for example, when generics can enter), but it does not automatically move a branded drug to “Tier 3.” In the US, formulary placement is decided by each insurer or pharmacy benefit manager (PBM), usually based on contracting and relative cost-effectiveness—not on patent status alone.

Why tier placement changes (or doesn’t) after patent expiry

Even after a patent expires, a drug may stay on a higher tier if:
- No generic (or preferred alternative) is available yet.
- The insurer has negotiated pricing that makes the branded product comparable to lower tiers.
- A long-acting or “authorized” product remains protected by other exclusivities (such as regulatory exclusivity), delays, or separate patents covering formulations or methods of use.
- Patient-use restrictions, step therapy, or prior authorization are used instead of changing tiers.

When do insurers move drugs to Tier 3 specifically?

Tier 3 is commonly where a plan places non-preferred brands or certain generics/alternatives depending on that plan’s structure. Many plans move to a lower tier once generics become available because they can reduce copays. But the timing varies by:
- When FDA approval and launch occur for generics/biosimilars
- The plan’s annual formulary review cycle and contract updates
- Switching policies (some plans still keep a brand temporarily to manage utilization)

Do providers control the tier, or do insurers control it?

Providers generally prescribe the medication; the insurer/PBM controls the formulary tier and the patient’s cost-sharing. So a physician does not usually “move” a drug to Tier 3 after patent expiry. Patients usually see the change first through pharmacy benefit coverage and copay updates.

What you can check if you want to know about a specific drug

To predict tier movement, check:
- Your plan’s current formulary entry for the drug and its tier
- Whether an FDA-approved generic/biosimilar is already listed and available
- Whether the plan uses preferred brand tiers vs. non-preferred brand tiers

If you share the drug name and the type of plan (employer plan, Medicare Part D, Medicaid managed care), I can help you map what usually happens to tiers for that situation.



Other Questions About Care :

damodaran unlevered beta us hospital/healthcare facilities january 2025 damodaran january 2025 unlevered beta hospitals healthcare facilities is stelara covered by medicare part b xarelto medicare i am an academic researching healthcare policy and outcomes, and i value rigorous methods, transparent data, and balanced interpretation over advocacy or talking points. i'm looking for medical techno Does liver function testing need extra care with lipitor st john's wort? I am a healthcare provider who evaluates treatment options diagnostic services medications and animal health products to make informed recommendations for the patients and animals in my care i'm l?